Previous Page  9 / 19 Next Page
Information
Show Menu
Previous Page 9 / 19 Next Page
Page Background

Gastro Education 2018

Journal of Clinical Gastroenterology and Hepatology

ISSN: 2575-7733

Page 23

September 06-07, 2018

London, UK

14

th

International Conference on

Gastro Education

I

n the United States of America, colorectal cancer is the fourth

commonest type of cancer and the second leading cause

of cancer-related mortality. Colonoscopy is the first line to

prevent and treat colorectal cancer. Colon and rectal cancer

survival depend largely on the disease stage. Generally, the

earlier the disease is diagnosed, the longer the survival. The

5-year survival rate for patients with early disease (limited to

the intestinal mucosa) is 90%, that for regional disease (with

lymph node involvement) is 68%, and that for metastatic

disease is only 10%. Reduction of CRC incidence and mortality

is the most relevant and important outcome for those who

perform colonoscopy; thus, evaluation of this goal is essential.

Risk of interval cancer is another outcome parameter. A

high-quality colonoscopy decreases the chance of missing

or misdiagnosing existing lesions, and recommendations for

screening are made under these assumptions. In this context,

measuring quality of care in ways related to significant patient

outcomes is a widely shared goal, and, among them the

adenoma detection rate (ADR). The adenoma detection rate

(ADR), in as much as it has been tied both to interval cancer

occurrence and to colon cancer mortality. Currently, ADR has

been gaining more and more international recognition as a

quality indicator ADR is the only factor that correlates with

the diagnosis of interval cancer; a higher ADR is associated

with a lower incidence of interval cancer. The ADR is the

percentage of colorectal adenomas histologically proven

by screening colonoscopies performed by a physician or a

service. Currently, ASGE recommends an ADR of 20% or more

for female patients and 30% for male patients; however, there

is a lack of data regarding the validation of this goal. In this

view, the systematic review about this topic is very important. I

intend to speak about this topic.

Biography

Michele de Lemos Bonotto pursued her Master’s Degree in Medicine at Lis-

bon University, Portugal (2017) and Health Science University from Porto

Alegre, Brazil (2017). She graduated in Gastroenterology from the same

university (2014) and is an Endoscopist Specialist at Brazilian Society of Di-

gestive Endoscopy (2015). She is currently working at endoscopy center of

Santa Casa Hospital and Moinhos Hospital respectively.

mime.b@icloud.com

Colorectal cancer is the third commonest cancer in men and

the second in women worldwide

Michele de Lemos Bonotto

1,2,3

1

Federal University of Health Sciences of Porto Alegre, Brazil

2

Santa Casa de Misericordia, Brazil

3

Hospital Moinhos de Vento Brazil

Michele de Lemos Bonotto, J Clin Gastroenterol Hepatol 2018, Volume 2

DOI: 10.21767/2575-7733-C2-005